Send to

Choose Destination
Cureus. 2016 Jul 7;8(7):e675. doi: 10.7759/cureus.675.

Stability of Programmable Shunt Valve Settings with Simultaneous Use of the Optune Transducer Array: A Case Report.

Author information

Department of Neurological Surgery, University of California, San Francisco.
Department of Neurological Surgery, University of California, San Francisco ; Research Fellow, Howard Hughes Medical Institute.
Department of Neuro-oncology, University of California, San Francisco.


The OptuneĀ®Ā transducer array (Novocure Ltd., Haifa, Israel) is an FDA-approved noninvasive regional therapy that aims to inhibit the growth of glioblastoma multiforme (GBM) cells via utilization of alternating electric fields. Some patients with GBM may develop hydrocephalus and benefit from subsequent shunt placement, but special attention must be paid to patients in whom programmable valves are utilized, given the potential effect of the magnetic fields on valve settings. We present the first case report illustrating the stability of programmable shunt valve settings in a neurosurgical patient undergoing therapy with the Optune device. In this study, shunt valve settings were stable over a period of five days despite Optune therapy. This is reassuring for patients with GBM who require simultaneous treatment with both the Optune device and a programmable shunt system.


glioblastoma multiforme; hydrocephalus; optune transducer array; shunt valve

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center